Hormone Therapy for Lung Cancer Baltimore MD

Taking a combination form of hormone replacement therapy, which includes both estrogen and progestin, increases a woman's risk for dying from lung cancer, a new study has found. The finding stems from an analysis of data from the Women's Health Initiative trial on 16,608 postmenopausal women, aged 50 to 79, in the United States who had been randomly assigned to take either a once-daily tablet of 0.625 milligrams conjugated equine estrogen plus 2.5 mg medroxyprogesterone acetate or a placebo.

Maryland General Hospital
(410) 225-8000
827 Linden Avenue
Baltimore, MD
specialty
General medical surgical
Hospital Type
Nongovernment, Not-for-profit
Hospital System
University of MD Medical Syst

Data Provided by:
Va Maryland Health Care System
(410) 605-7001
10 North Greene Street
Baltimore, MD
specialty
General medical surgical
Hospital Type
Government, federal
Hospital System
Department of Veterans Affairs

Data Provided by:
Union Memorial Hospital
(410) 554-2000
201 East University Parkway
Baltimore, MD
specialty
General medical surgical
Hospital Type
Nongovernment, Not-for-profit
Hospital System
MedStar Health

Data Provided by:
University Specialty Hospital
(410) 547-8500
601 South Charles Street
Baltimore, MD
specialty
Chronic disease
Hospital Type
Nongovernment, Not-for-profit
Hospital System
University of MD Medical Syst

Data Provided by:
Kennedy Krieger Institute
(443) 923-9200
707 North Broadway
Baltimore, MD
specialty
Children's other specialty
Hospital Type
Nongovernment, Not-for-profit

Data Provided by:
Mercy Medical Center
(410) 332-9000
301 St Paul Place
Baltimore, MD
specialty
General medical surgical
Hospital Type
Nongovernment, Not-for-profit

Data Provided by:
Univ Of Maryland Med Center
(410) 328-8667
22 South Greene Street
Baltimore, MD
specialty
General medical surgical
Hospital Type
Nongovernment, Not-for-profit
Hospital System
University of MD Medical Syst

Data Provided by:
Bon Secours Baltimore System
(410) 362-3000
2000 West Baltimore Street
Baltimore, MD
specialty
General medical surgical
Hospital Type
Nongovernment, Not-for-profit
Hospital System
Bon Secours Health System, Inc

Data Provided by:
Johns Hopkins Hospital
(410) 955-5000
600 North Wolfe Street
Baltimore, MD
specialty
General medical surgical
Hospital Type
Nongovernment, Not-for-profit
Hospital System
Johns Hopkins Health System

Data Provided by:
Levindale Hebrew Ger Ctr
(410) 466-8700
2434 West Belvedere Avenue
Baltimore, MD
specialty
Long-Term Acute Care
Hospital Type
Nongovernment, Not-for-profit
Hospital System
LifeBridge Health

Data Provided by:
Data Provided by:

Hormone Therapy for Lung Cancer

Provided By:

SATURDAY, Sept. 19 (HealthDay News) -- Taking a combination form of hormone replacement therapy, which includes both estrogen and progestin, increases a woman's risk for dying from lung cancer, a new study has found.

The finding stems from an analysis of data from the Women's Health Initiative trial on 16,608 postmenopausal women, aged 50 to 79, in the United States who had been randomly assigned to take either a once-daily tablet of 0.625 milligrams conjugated equine estrogen plus 2.5 mg medroxyprogesterone acetate or a placebo.

After eight years, 73 women taking the hormone therapy and 40 women in the placebo group had died of lung cancer. That meant, according to the researchers, that women who took the drug were 71 percent more likely to die from the disease.

The study also found that women taking the hormone therapy were 28 percent more likely to be diagnosed with lung cancer, although the study noted that the finding was not statistically significant.

"Treatment with estrogen plus progestin in postmenopausal women ... increased the number of deaths from lung cancer, in particular deaths from non-small-cell lung cancer," concluded Rowan Chlebowski, of the Los Angeles Biomedical Research Institute at Harbour-UCLA Medical Center, and his colleagues.

The researchers urged that the findings "be incorporated into risk-benefit discussions with women considering combined hormone therapy, especially those with a high risk of lung cancer ... such as current smokers or long-term past smokers."

Dr. Apar Kishor Ganti, from the University of Nebraska Medical Center in Omaha, wrote in an accompanying editorial that "because the optimum safe duration of hormone-replacement therapy in terms of lung cancer survival is unclear, such therapy should probably be avoided in women at a high risk of developing lung cancer, especially those with a history of smoking."

In fact, Ganti questioned whether hormone therapy should be used at all.

"These results, along with the findings showing no protection against coronary heart disease, seriously question whether hormone-replacement therapy has any role in medicine today," he wrote. "It is difficult to presume that the benefits of routine use of such therapy for menopausal symptoms outweigh the increased risks of mortality, especially in the absence of improvement in the quality of life."

The study, which appears online and in an upcoming print issue of The Lancet, was released Sept. 19 to coincide with the European Cancer Organization meeting.

More information

The U.S. National Institute on Aging has more on hormones and menopause.

SOURCE: The Lancet, news release, Sept. 19, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com